The United Kingdom aims to boost its life sciences profile as Aviva Capital Partners and Socius unveiled plans for a £1 ...

The FDA has freed Amgen’s mysterious early-stage obesity asset from a clinical hold, with the phase 1 study now enrolling ...

Scholar Rock is shaking up its executive team as it prepares to enter the commercial arena with the expected launch of spinal ...

To REMS, or not to REMS. That apparently was the question for Cytokinetics, which has seen any potential approval for its ...

Pliant will be cutting 45% of staffers as part of a “strategic restructuring of its workforce," the biotech announced after ...

The National Institutes of Health (NIH) is making a major change to how grant recipients can use their funds. | The National ...

The U.S. government is putting down $500 million toward the development of a “universal” vaccine—a shot designed to protect ...

With the walls quickly closing in, Kronos Bio has accepted a buyout from notorious biotech acquirer Concentra Biosciences. | ...

Following the launch of two new cancer tests—plus a third planned for before the end of 2025—Exact Sciences is nudging up its ...

Edwards Lifesciences has claimed a groundbreaking approval from the FDA that opens up its minimally invasive heart valve ...

Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor (ER) degrader R&D plan in the wake of mixed data ...

Orphan drug specialist Amicus Therapeutics is paying Dimerix $30 million cash for U.S. rights to the phase 3 prospect DMX-200 ...